OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

Musk’s criticisms have escalated into legal actions. In February, he filed a lawsuit against OpenAI, accusing it of breaching its nonprofit mandate. Although the lawsuit was withdrawn in June, Musk refiled it in August, further intensifying the conflict.

The feud between Elon Musk and Sam Altman has been years in the making, litigious, and above all else, personal. Or at least it used to be. Now Musk is holding Altman’s feet to the fire for his wavering loyalties to President Donald Trump.

Sam Altman-led OpenAI is reportedly engaged in intricate discussions to transform into a for-profit entity, but its board is grappling with valuing Microsoft's stake while negotiating the worth of its new charitable division at $30 billion.

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure cancer. We’ve all heard such blusterous aspirational hype before, to be sure.

Cathie Wood and her Ark Invest funds sold Oklo — the nuclear power startup backed by OpenAI head Sam Altman — and purchased uranium refiner Cameco on Tuesday ahead of President Donald Trump's announcement of a private sector investment of up to $500 billion to fund infrastructure for artificial intelligence.

Oracle stock took off as President Trump announced the Stargate AI infrastructure project. Read why I maintain my buy rating for ORCL stock.

OpenAI is taking steps to transform its AI-powered chatbots into autonomous software engineers, aiming to redefine the future of artificial general intelligence, according to The Information.

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

San Francisco, Jan 23 (IANS) The xAI owner Elon Musk and OpenAI CEO Sam Altman are fighting on X about Stargate, the enormous infrastructure project to build data centres for OpenAI across the US.

Stargate CEOs cite project’s promise of enabling cancer vaccines, though Musk joins critics in questioning partners’ financial strength and wisdom of the joint venture.